Primary and secondary prevention of liver cancer caused by HBV

Frontiers in Bioscience - Scholar

Volumn 2 S, Issue 2, 2010, Pages 756-763

  Blumberg, Baruch S ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

HBV; HCC; Hepatitis B Virus; Hepatocellular carcinoma; Prevention by delay; Primary prevention; Review; Secondary prevention; Treatment; Vaccine

Indexed keywords

HEPATITIS B VACCINE;

HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGY; LIVER CELL CARCINOMA; LIVER TUMOR; REVIEW; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS;

EID: 77956314908     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s98     Document Type: Article

References (36)

1. B. S. Blumberg, and W. T. London: Hepatitis B virus and the prevention of primary hepatocellular carcinoma. Editorial. N. Engl. J. Med. 304, 782-784 (1981) (Pubitemid 11153774)
2. M. Payet, R. Camaine, and P. Rene: Le cancer primitive du foie, etude critique a propos de 240 cas. Rev. Intern. Hepatol. 4, 1-20 (1956)
3. E. Steiner and J. N. Davies: Cirrhosis and primary liver carcinoma in Uganda Africans. Br J Cancer Dec 11, 523-34 (1957)
4. J. B. Smith and B. S. Blumberg: Viral hepatitis, post-necrotic cirrhosis and hepatocellular carcinoma. Lancet 2, 953 (1969)
5. R.P. Beasley: Hepatitis B virus - the major etiology of the hepatocellular carcinoma. Cancer 1942, 61 (1988)
6. B. S. Blumberg, I. Millman, P. S. Venkateswaran, and S. P. Thyagarajan, Hepatitis B virus and hepatocellular carcinoma-treatment of HBV carriers with Phyllanthus amarus. Boca Raton, FL: Cancer Detection and Prevention, Nieburgs, H. E. (Ed.) CRC Press Inc., Boca Raton FL, 195-201, (1989)
7. H. Popper, L. Roth, R.H. Purcell, B.C. Tennant, J.L. Gerin: Hepatocarcinogenicity of the woodchuck hepatitis virus. Proc Natl Acad Sci USA 84, 866 (1987)
8. C-Y. Kim, K. Koike, I. Saito, T. Miyamura, and G. Jay: HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351, 317 (1991)
9. H. Ueda, S.J. Ullrich, J.D. Gangemi, C.A. Kappel, L. Ngo, M.A. Feitelson, and G. Jay. Functional inactivation but not structural mutation of p53 causes liver cancer. Nature Genetics 9, 41-47 (1995)
10. B. S. Blumberg: Australia antigen and the biology of hepatitis B. Science 197, 17-25 (1977) (Pubitemid 8128337)
11. B. S. Blumberg and I. Millman: Vaccine Against Viral Hepatitis and Process. US Patent #3, 636, 191, Filed Oct. 8, 1969 Issued Jan. 18, 1972
12. B. S. Blumberg, Hepatitis B. The Hunt for a Killer Virus. Princeton NJ: Princeton University Press, Princeton NJ (2002)
13. W. Szmuness, C. E. Stevens, E. J. Harley, E. A. Zang, W. R. Oleszko, D. C. William, R. Sadovsky, J. M. Morrison, and A. Kellner: Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. Oct 9, 303, 833-841 (1980) (Pubitemid 10014927)
14. W. Szmuness, C.E. Stevens, E.A. Zang, E.J. Harley, and A. Kellner. A controlled clinical trial of the efficacy of the hepatitis B vaccine (heptavax B); a final report. Hepatology 1: 377-385 (1981) (Pubitemid 12218155)
15. F. Tsuda, A. Machida, S. Mishiro, T. Nakamura, Y. A synthetic peptide vaccine involving the product of the pre-S (2) region of hepatitis B virus DNA: protective efficacy in chimpanzees. PNAS December 1, 1986 Vol. 83 no. 23 9174-9178
16. M. H. Chang, C. J. Chen, M. S. Lai, H. M. Hsu, T.C. Wu, M.S. Kong, D.C. Liang, W. Y. Shau, and D.S. Chen: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 336, 1855-1859 (1997)
17. M-S. Lee, D-H. Kim, H. Kim, H-S. Lee, C-Y Kim, T-S. Park, K-Y. Yoo, B-J. Park and Y-O. Ahn: Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: a cohort study in Korea. Int. J. Epidemiol. 27, 316-319 (1998) (Pubitemid 28203802)
18. L. E. Markowitz, E.F. Dunne, M. Saraiya, H. W. Lawson, H. Chesson, and E. R. Unger: Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent Human Papilloma virus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. Mar 23, 56 (RR-2), 1-24 (2007)
19. E. Elbasha, E.J. Dasbach, R.P. Insinga. Model for assessing human papilloma virus vaccination. Emerg Infect Dis; 13:29-41 (2007)
20. B. Tang, W.D. Kruger, G. Chen, F. Shen, W.Y. Lin, S. Mboup, W. T. London, and A.A. Evans: Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J Med Virol. 72, 35-40 (2004) (Pubitemid 37484740)
21. C. J. Chen, H. I. Yang, J. Su, C.L. Jen, S.L. You, S. N. Lu, G.T. Huang, U.H. Iloeje: REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295, 65-73 (2006) (Pubitemid 43042691)
22. U. H. Iloeje, H. I. Yang, J. Su, C. L. Jen, S.L. You, and C. J. Chen: Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology, 678-86 (2006)
23. C. Niederau, MD, T. Heintges, MD, S. Lange, MD, G. Goldmann, MD, C. M. Niederau, MD, L. Mohr, MD, and D. Häussinger, MD: Long-Term Follow-Up of HBeAg-Positive Patients Treated with Interferon Alfa for Chronic Hepatitis B. N Engl J Med 334, 1422-1427 (1996) (Pubitemid 26157437)
24. Y. F. Liaw, J. J. Sung, W. C. Chow, G. Farrell, C. Z. Lee, H. Yuen, T. Tanwandee, Q. M. Tao, K. Shue, O. N. Keene, J. S. Dixon, D. F. Gray, and J. Sabbat: Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 351, 1521-1531 (2004)
25. P. Andreone, A. Gramenzi, C. Cursaro, M. Biselli, C. Cammà, F. Trevisani, and M. Bernardi: High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat. 11, 439-442 (2004) (Pubitemid 39336225)
26. G.M. Peters, H.W. Hann, P. Martin, E.J. Heathcote, P. Buggisch, R. Rubin, M. Bourliere, K. Kowdley, C. Trepo, D. F. Gray, M. Sullivan, K. Kleber, R. Ebrahimi, S. Xiong, and C.L. Brosgart. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B, Gastroenterology. 126, 91-101 (2004) (Pubitemid 38040727)
27. P. Marcellin, G.K.K. Lau, F. Bonino, P. Farci, S. Hadziyannis, R. Jin, Z-M. Lu, T. Piratvisuth, G. Germanidis, C. Yurdaydin, M. Diago, S. Gurel, M-Y. Lai, P. Button, N. Pluck. Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B for the Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group, New Eng. J. Med., 351, 1206-17, (2004) (Pubitemid 39296307)
28. Web site of the Hepatitis B Foundation (www.hepb.org).
29. D. Van der Poorten, D. T. Kenny, T. Butler, and J. George: Liver disease in adolescents: a cohort study of high-risk individuals. Hepatology 46, 1750-1758 (2007)
30. B. S. Blumberg: Bioethical questions related to hepatitis B antigen. Am. J. Clin. Pathol. 65, 848-853 (1976)
31. B. S. Blumberg and R. C Fox: The Daedalus effect: Changes in ethical questions relating to hepatitis B virus. Ann. Intern. Med. 102, 390-394 (1985) (Pubitemid 15134683)
32. B. S. Blumberg, B Larouze, W. T. London, B. Werner, J. E. Hesser, I. Millman, G. Saimot and M. Payet: The relation of infection with the hepatitis B agent to primary hepatic carcinoma. Am. J. Pathol. 81, 669-682 (1975)
33. B. S. Blumberg and W. T. London: Hepatitis B virus and the prevention of primary hepatocellular carcinoma. Editorial. N. Engl. J. Med. 304, 782-784 (1981) (Pubitemid 11153774)
34. th edition ), Philadelphia Lippincott Williams and Wilson, 2005 Philadelphia (2005)
35. M. Nunez: Hepatitis B Virus May Be a Risk Factor for Other Cancers Besides Hepatocellular Carcinoma. Digestive Disease Week, Abstracts (2005)
36. M. H. Manal, D. Li, S. E-D. Adel, R.A. Wolf, M.L. Bondy, M. Davila, and J.L. Abbruzzese. Association between Hepatitis B virus and pancreatic cancer. J. Clin. Oncol. 26, 4557-4562 (2008)